Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01285453 | Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors | PHASE1 | COMPLETED | 9 | — | — | Mar 1, 2009 | - | Dec 9, 2020 | 2 | Japan |
| Arm | Type | Description |
|---|---|---|
| ASA404 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vadimezan | DRUG | - |
Inclusion Criteria: 1. Patients with confirmed solid tumors whose disease has progressed or recurred after treatment at lease one therapy, except docetaxel 2. WHO Performance Status of 0-1 Exclusion Criteria: 1. Patients having symptomatic CNS tumor/metastasis and requiring treatment 2. Patients ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |